

Q3 2026

Strategy Execution Drives Strong and Profitable Growth

November 5th, 2026

CEO Michael Akoh
CFO Børge Sørvoll
CCO Paul Blackburn

ArcticZymes Technologies

Disclaimer

This presentation contains certain forward-looking information and statements. Such forward-looking information and statements are based on the current, estimates and projections of the Company or assumptions based on information currently available to the Company. Such forward-looking information and statements reflect current views with respect to future events and are subject to risks, uncertainties and assumptions. The Company cannot give assurance to the correctness of such information and statements. These forward-looking information and statements can generally be identified by the fact that they do not relate only to historical or current facts.

Forward-looking statements sometimes use terminology such as "targets", "believes", "expects", "aims", "assumes", "intends", "plans", "seeks", "will", "may", "anticipates", "would", "could", "continues", "estimate", "milestone or other words of similar meaning and similar expressions or the negatives thereof. By their nature, forward-looking information and statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements that may be expressed or implied by the forward-looking information and statements in this presentation. Should one or more of these risks or uncertainties materialize, or should any underlying assumptions prove to be incorrect, the Company's actual financial condition or results of operations could differ materially from that or those described herein as anticipated, believed, estimated or expected.

Any forward-looking information or statements in this presentation speak only as at the date of this presentation. Except as required by the Oslo Stock Exchange rules or applicable law, the Company does not intend, and expressly disclaims any obligation or undertaking, to publicly update, correct or revise any of the information included in this presentation, including forward-looking information and statements, whether to reflect changes in the Company's expectations with regard thereto or as a result of new information, future events, changes in conditions or circumstances or otherwise on which any statement in this presentation is based.

Given the aforementioned uncertainties, prospective investors are cautioned not to place undue reliance on any of these forward-looking statements.

ArcticZymes Technologies

Agenda

1. Q3 Highlights and Strategy
2. Commercial Update
3. Financial Performance
4. Outlook and summary
5. Q & A

ArcticZymes Technologies

Q3 2026 · HIGHLIGHTS

Continued growth in Q3

FINANCIAL PERFORMANCE

TOTAL REVENUE · MNOK

33.0

▲ +11%

9 months

102.0

▲ +22%

SALES REVENUE · MNOK

32.9

Constant Exchange Rates
35.3 MNOK · +24%

▲ +15%

9 months

96.6

Constant Exchange Rates · +33%

▲ +23%

EBITDA · MNOK

3.1

▼ −11% YoY

9 months

12.1

▲ +227% YoY

MILESTONES

BIOMANUFACTURING · +44%

CDMO sales more than doubled

New CDMO adopts M-SAN for in vivo CAR-T

MOLECULAR TESTING

Embedded in oncology workflows

AZ Proteinase a critical kit component

INNOVATION

RNA therapeutics market entry

Launched 27 October 2026:
RiboClean™ dsDNase and RiboCleave™ 1
In discussion with CDMOs

ArcticZymes Technologies

Building a Scalable Enzyme Platform

Strategic pillars accelerating growth and resilience

Umbrella Strategy

1. **Customer focused market approach**
   Transition from product-oriented enzyme supplier, to a customer centric, application lead/solutions provider

2. **Create a wider base – diversification**
   Increase the number of markets addressed and products sold

Strategic Pillars

Molecular tools



Viral Vectors



RNA Therapeutics



Channel



ArcticZymes Technologies


Commercial Update Q3 2026




ArcticZymes Technologies

Q3 2026 Sales Highlights

Double-digit growth for a third quarter / +24% at constant currency



32.9 MNOK | +15% YoY
+4.4 MNOK vs Q3 2025
~7% FX headwind



Highest quarter of 2026

Increasing Momentum

ArcticZymes Technologies

Regional Performance

Europe leads growth, US recovering as predicted, APAC momentum broadens reach


Europe **18.9 MNOK**		**+26% YoY**	EU CDMOs Contributed most, UK slower
US **12.1 MNOK**		**Flat YoY**	US East recovering, US Central slower
APAC **1.9 MNOK**		**+40% YoY**	Larger distributor orders in India and China; Focus on Japan projects

Europe delivers 88% of Q3 growth; APAC +40%; US holding steady

ArcticZymes Technologies

Biomanufacturing

CDMOs scaling into GMP manufacturing power a breakout quarter



Biomanufacturing

18.8 MNOK | +44% YoY
+18% QoQ
3rd-best quarter ever

Biomanufacturing in Q3: what matters

7.0	**GMP sales +227% YoY** MNOK in Q3 vs 2.1
+6.5	**M-SAN HQ is the growth engine** MNOK YoY (+165%); SAN HQ, HL-SAN slightly lower
2x	**Direct CDMO sales doubled (+5.3 MNOK)** Six customers above 1 MNOK in Q3 – all CDMOs
+45%	**Larger orders lift order value** Avg order 75.0 vs 51.6 kNOK, on larger CDMO orders


Strongest quarter since Q4 2022

GMP now 37% of segment sales (16%)

ArcticZymes Technologies

Molecular Tools

A pause after a record run – the underlying trend remains upward



Molecular Tools

14.1 MNOK | -8% YoY
9M: +39% YoY
Production re-run

Molecular Tools in Q3: what matters

4 of 4	**Key product groups on track for 2026**
72	**More paying customers** Up from 67 in Q3 2025 (+7.5%) – broader base
Q4	**Q3 orders shipping in Q4** Purchase orders roll into Q4 delivery

Phasing of deliveries impacted revenue

12-month average up 41% year on year

ArcticZymes Technologies

9M 2026 - Growth Sustained

Both segments growing / Sales +23% (+33% constant currency)

Total Sales

96.6 MNOK

- ▲ 23% growth YoY 2025
- ▲ +18.1 MNOK vs 9M 2025

Molecular Tools

46.6 MNOK

- ▲ 39% growth YoY 2025

Biomanufacturing

50.0 MNOK

- ▲ 11% growth YoY 2025

Q1–Q3 Revenues (MNOK)



ArcticZymes Technologies

RiboClean™ dsDNase

RiboCleave™ 1 GAA AU

Launched 27 October 2026 | Early-access programme under way

ArcticZymes Technologies

RNA Manufacturing, Explained Simply

Enzymes are precision tools – ours make RNA therapeutics cheaper and faster

1 Make the RNA

Drug developers make RNA -

Instructions that tell the body's cells how to fight disease.

mRNA vaccines

one well-known example

2 Clean up

RiboClean™

DNA from production must be removed.
RiboClean™ does this using far less enzyme.

>80%

lower nuclease cost per batch (modelled), using 10× less enzyme

3 Check quality

RiboCleave™ 1

Each batch is tested to confirm the RNA is correct.
RiboCleave™ 1 makes that test far faster.

6 hrs → 30 min

to prepare a sample for quality testing

ArcticZymes Technologies

Why It Matters

What the RNA enzyme launch delivers

FOR OUR CUSTOMERS

Lower cost per batch
RiboClean™ is modelled to cut nuclease cost by more than 80%, using 10× less enzyme.

Faster answers
RiboCleave™ 1 cuts a key quality test from about 6 hours to 30 minutes.

No trade-off
No detectable effect on RNA quality or yield, and it fits existing processes.

FOR ARCTICZYMES

Diversification
RNA becomes our third growth pillar, alongside Molecular Tools and Viral Vector.

An attractive growing market
RNA is the technology behind mRNA vaccines and a growing number of new treatments.

More steps to supply
RNA production needs many more enzymes than viral vector – room to grow as customers scale up.

Customers save time and cost – we build a more robust, diversified business

ArcticZymes Technologies

Financial Performance




ArcticZymes Technologies

Profitable growth – currency masks underlying momentum

Sales +15% reported, +23% at constant currency

Sales & EBITDA



	Q3		YTD	
	2026	2025	2026	2025
Sales revenues	32,9	28,5	96,6	78,5
Other revenues	0,1	1,2	5,5	5,0
Sum revenues	**33,1**	**29,7**	**102,1**	**83,6**
Cost of materials	-2,0	0,1	-4,3	-2,7
Change in inventory	-0,3	-0,8	-1,7	-0,4
Personnel expenses	-18,8	-18,9	-55,7	-51,3
Other operating expenses	-8,9	-6,7	-28,3	-25,4
Sum expenses	**-30,0**	**-26,2**	**-90,0**	**-79,9**
EBITDA	**3,1**	**3,5**	**12,1**	**3,7**
Depreciation and amortisation	-2,3	-2,2	-6,8	-6,7
EBIT	**0,9**	**1,3**	**5,3**	**-3,0**
Net financials	0,9	2,3	3,6	6,6
EBT	**1,9**	**3,6**	**8,8**	**3,5**

At constant currency (estimate):
Q3 2026 EBITDA of ~MNOK 5.5 (Q3 25: MNOK 3.5), margin ~16%
9M 2026 EBITDA of ~MNOK 19.8 (9M 25: MNOK 3.7), margin ~19%

ArcticZymes Technologies


Stronger NOK reduces reported sales by MNOK 2.4


NOK strengthened against EUR/USD

- Norwegian krone strengthened against the USD and the Euro in Q3 2026, and compared to Q3 2025
- Norwegian krone strengthened against USD and EURO in 9M 2026

Q3 2026	Q3 2026 CER	Recalculated	
32.9 MNOK	35.3 MNOK	2.4 MNOK	7%

9M 2026	9M 2026 CER	Recalculated	
96.6 MNOK	104.3 MNOK	7.7 MNOK	7%





ArcticZymes Technologies

Cost reflect growth investments and temp. items

Commercial execution prioritised

Temporary or timing-related

- MNOK 0.7 production re-run cost. Under control now
- Currency headwind

Growth-related

- Increased development activity for new launches (MNOK 1.5 capitalised)
- Higher bonus accrual reflecting performance
- External consultancy supporting growth initiatives


	Q3		YTD	
	2026	2025	2026	2025
Sales revenues	32,9	28,5	96,6	78,5
Other revenues	0,1	1,2	5,5	5,0
Sum revenues	**33,1**	**29,7**	**102,1**	**83,6**
Cost of materials	-2,0	0,1	-4,3	-2,7
Change in inventory	-0,3	-0,8	-1,7	-0,4
Personnel expenses	-18,8	-18,9	-55,7	-51,3
Other operating expenses	-8,9	-6,7	-28,3	-25,4
Sum expenses	**-30,0**	**-26,2**	**-90,0**	**-79,9**
EBITDA	**3,1**	**3,5**	**12,1**	**3,7**
Depreciation and amortisation	-2,3	-2,2	-6,8	-6,7
EBIT	**0,9**	**1,3**	**5,3**	**-3,0**
Net financials	0,9	2,3	3,6	6,6
EBT	**1,9**	**3,6**	**8,8**	**3,5**

ArcticZymes Technologies

Cash flow and short-term investments

Strong cash position supports future growth

Cash and STI position



*includes changes in STI of +0.8 MNOK

Outlook and Summary



ArcticZymes Technologies

Priorities Unchanged | Execution excellence

Focused execution against the Capital Markets Day priorities

OUR AMBITION

Sustainable double-digit growth, targeting outperformance of served markets:

- EBITDA margin expansion through operating leverage
- Stronger cash generation and financial flexibility
- Selective, value-accretive investments

OUR EXECUTION

Core priorities (2026-2028):

- Scale a high-performance commercial engine
- Innovation through internal R&D and partnerships
- Expand SAN (GMP) penetration in CDMOs
- Expand NGS/metagenomics exposure
- Establish RNA as a scalable growth pillar

» Focused growth

» Increased operational leverage

ArcticZymes Technologies

Executing on our five priorities presented at the CMD

Q3 delivery on strategic objectives

	2026–2028 CORE PRIORITY	PROOF	DELIVERY DETAIL	NEXT PROOF POINT
1	**Scale a high-performance commercial engine**	**+15%**	9M sales growth | +33% at constant currency	Repeat orders and broader account penetration
2	**Innovation through internal and external partnerships**	**2 enzymes**	RiboClean™ and RiboCleave™ 1 developed and launched	4 beta-site testers provided data and application feedback to support launch
3	**Expand SAN (GMP) penetration in CDMOs**	**+227%**	GMP sales: 37% of Biomanufacturing Q3 revenue – sales to CDMO doubled	Further GMP adoption and additional CDMO programme inclusion
4	**Expand NGS / metagenomics exposure**	**+39%**	9M Molecular Tools growth which includes NGS	New workflows, deeper customer adoption and partner
5	**Establish RNA as a scalable growth pillar**	**2 launches**	RiboClean™ and RiboCleave™ 1 launched 27 October	Early-access evaluations and first commercial orders

Tangible Q3 execution progress

Summary

A broader and more embedded enzyme platform

GROWTH

+23%

Nine-month sales growth, +33% at CER

PROFITABILITY

NOK 12.1m

Nine-month EBITDA, up from NOK 3.7m a year ago

LEVERAGE

+23% / +13%

Sales growth vs. operating expense growth, 9M

STRENGTH

NOK 272m

Board has asked management to evaluate capital allocation options, including a potential share buyback and the possible use of treasury shares in future acquisitions

Going into Q4 with business momentum

ArcticZymes Technologies


ArcticZymes
Technologies
Thank you
Q & A